A preemptive low dose of the nonsteroidal anti-inflammatory drug (NSAID) etoricoxib may reduce the need for analgesics after third-molar surgery, based on the results of a randomized clinical trial ...

Washington DC - An FDA memo shows that there are concerns over an increase in cardiovascular risk with 2 new COX-2 selective inhibitors that are awaiting approval in the US—etoricoxib (Arcoxia, Merck ...

The US FDA has deemed that the new selective COX-2 inhibitor, etoricoxib (Arcoxia ®, Merck & Co), is "approvable" but says that additional data on safety and efficacy are required before the approval ...

Oral etoricoxib is at least as effective as other drugs commonly used for pain relief after surgery. A Cochrane Systematic Review has confirmed the effectiveness of the drug, which is sold under the ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Background: Preclinical data clearly demonstrated ...